Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
Purple Biotech Ltd. - American Depositary Shares (PPBT)
Company Research
Source: GlobeNewswire
Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control of 79% reduction in risk of death (HR 0.21, P = 0.04) with median OS improvement of 5.1 months and over 90% reduction in risk of progression or death (HR Phase 2b clinical study is planned in multiple selected indications, potentially targeting patients based on biomarkers REHOVOT, Israel, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today reported positive final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CE
Show less
Read more
Impact Snapshot
Event Time:
PPBT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PPBT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PPBT alerts
High impacting Purple Biotech Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
PPBT
News
- Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares [Yahoo! Finance]Yahoo! Finance
- Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary SharesGlobeNewswire
- Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares [Yahoo! Finance]Yahoo! Finance
- Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary SharesGlobeNewswire
- Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer [Yahoo! Finance]Yahoo! Finance
PPBT
Analyst Actions
- 11/15/24 - HC Wainwright
PPBT
Sec Filings
- 12/6/24 - Form 6-K
- 12/5/24 - Form 6-K
- 12/4/24 - Form 6-K
- PPBT's page on the SEC website